{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-003881","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.388214+00:00","generated_at":"2026-06-27T08:51:33.969480+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo reports Q2 FY2022 net loss $1.1M; starts Phase 2 trial for ANEB-001; appoints new CEO","bullets":["Net loss $1.1M ($0.05/sh) vs $0.3M ($0.03/sh) in Q2 FY2021; operating expenses $1.1M.","Cash and cash equivalents $18.0M as of Dec 31, 2021; cash burn $1.2M in Q2.","Initiated Phase 2 proof-of-concept study for ANEB-001 for acute cannabinoid intoxication; topline results expected H1 2022.","Simon Allen appointed CEO effective Feb 1, 2022; previously CBO at Ambrx.","FDA pre-IND meeting provided guidance; U.S. patent issued for ANEB-001 (expires 2040)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-003881","json":"https://secwatch.observer/filing/0001493152-22-003881.json","markdown":"https://secwatch.observer/filing/0001493152-22-003881.md","text":"https://secwatch.observer/filing/0001493152-22-003881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222003881/0001493152-22-003881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222003881/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:51:33.969480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}